GINGERA MIDLIFE, UNDERSTOOD
← The reading room
Hormones & treatment · 12 MIN READ

Can Postmenopausal Women Use Testosterone? Evidence and Gaps After the FDA Workshop

Full original restored

The supported use has clear limits. Claims about energy, brain fog and anti-ageing cannot borrow the same evidence.

Editorial image
In this article
Complete manuscript restored from the archive, with a full English translation. Original medical claims have been preserved for review; medical and regional terminology review remain pending. This is educational reading, not individual medical advice.

1. Women have testosterone too, but there is no “below this level, supplement it” cutoff

Testosterone is often called a “male hormone,” but women’s ovaries and adrenal glands also produce androgens. Blood testosterone concentrations are much lower in women than in men. Different hormones also have different measurement units, binding states, and sampling times, so a fixed ratio such as “testosterone is ten to twenty times estradiol” cannot describe a woman’s entire life. More importantly, a blood-test value alone cannot diagnose a woman’s need for testosterone treatment.[1,3]

Hot flashes, sleep changes, or reduced sexual desire after menopause often have more than one cause. Vaginal pain, medication, chronic conditions, mood, and relationship circumstances can all affect desire; fatigue and “brain fog” are not synonymous with androgen deficiency either. Attributing all these difficulties to “low testosterone” conflates problems that need separate attention.[1,3]

On September 17, 2026, the FDA held a public workshop on “Testosterone Use in Menopausal Women,” covering efficacy evidence, measurement methods, dose selection, and long-term safety. The workshop was a regulatory discussion, not a marketing approval or a treatment recommendation for all menopausal women. The Federal Register also invited public comments on future drug development, with a deadline of October 19, 2026.[4]

First distinguish three levels

That women have testosterone is a physiological fact; that some postmenopausal women with low sexual desire may benefit from treatment is clinical evidence; that everyone should be tested or given testosterone is unsupported by evidence.[1–3]

2. Mechanisms: when periods end, what happens to androgens?

The ovaries and adrenal glands both contribute to androgen production in women, while peripheral tissues convert precursor hormones into active hormones. Wide-ranging physiological effects do not mean supplementation improves every related symptom. Treatment research needs to address specific populations, specific outcomes, and acceptable risks, rather than a single laboratory value.[1,3]

Around natural menopause, changes in estradiol are closely tied to declining ovarian function. Age-related androgen changes do not follow exactly the same trajectory, and surgical removal of the ovaries cannot be equated with natural menopause. Current consensus has not established a blood threshold for diagnosing “female testosterone deficiency.” Whether low desire constitutes a disorder depends on persistence, whether the individual is distressed by it, and other contributing factors.[1,3]

Evidence-supported uses must be distinguished from uses to which that evidence cannot yet be extended:

  • Low sexual desire (HSDD, or hypoactive sexual desire disorder): This currently has the strongest evidence. It enters the discussion only when low desire persists, causes substantial distress, and other causes such as depression, medication, thyroid problems, and relationship factors have been excluded.
  • Energy, mood, and cognition: Someone’s report of feeling better cannot justify promoting it as an indication for fatigue or “brain fog.” Randomized trials have not established reliable cognitive benefit.[1,2]
  • Muscle and bone: Research is insufficient to support testosterone for preventing osteoporosis or falls, or as an antiaging treatment.[1,2]

Evidence-supported treatment is mainly limited to hypoactive sexual desire disorder (HSDD) in postmenopausal women after a complete assessment. This does not mean other symptoms are “not real”; it means existing trials do not establish that testosterone reliably improves them.[1–3]

Measurement has limitations too. Female testosterone concentrations are low, and some routine immunoassays lack sufficient accuracy in that range. A validated liquid chromatography–tandem mass spectrometry method (LC-MS/MS) can be used where available. Testing cannot diagnose HSDD, however; before and during treatment, it can help exclude already elevated levels and monitor whether concentrations exceed the female physiological range. Dose and follow-up still require assessment of symptoms and adverse effects.[3,4]

Original article illustration

Komodo Islands · NASA/JPL space imagery (PIA12061)

3. What trials support, and what regulators still need

Clinical research on testosterone use in women does exist. The distinctions to make are between indications defined by consensus, average efficacy estimated by randomized trials, and the remaining gaps in long-term safety.

A particularly representative document is the 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women (Davis et al., published in The Journal of Sexual Medicine and endorsed by eleven international medical societies). Its conclusion can be summarized in one sentence: the only current evidence-based indication is hypoactive sexual desire disorder (HSDD) in appropriately assessed postmenopausal women, using “physiological doses,” rather than “supraphysiological doses” above the normal range. The consensus also candidly notes that long-term safety data beyond twenty-four months remain limited, particularly for cardiovascular disease and breast cancer.

The 2021 ISSWSH guideline describes the clinical steps in greater detail: first assess biological, psychological, and relationship factors in HSDD, then discuss transdermal treatment; measure total testosterone before treatment and monitor it throughout, avoiding concentrations above the female physiological range. It does not support diagnosing HSDD directly from a low number.[3]

The 2019 systematic review by Islam et al. included 36 randomized trials and 8,480 women. Compared with placebo or a comparator, the mean difference in “satisfying sexual events” was 0.85 per month (95% confidence interval 0.52–1.18). This pooled trials of different formulations and administration routes; the entire 0.85 cannot be attributed to transdermal preparations. The average also does not mean every individual gains nearly one additional event. The review did not establish bone or cognitive benefits.[2]

Why does the United States still lack a female-specific formulation?

Historically, female-specific testosterone patches and gels entered regulatory or clinical development, with challenges involving efficacy endpoints, potential off-label use, and long-term safety. Projects did not all stop for the same reasons: lack of approval cannot simply be explained as “the drug does not work,” nor does it imply that “safety has been established.” The 2012 LibiGel paper by White et al. describes the study design of a long-term cardiovascular and breast-safety trial, not trial results.[6]

Regulatory status differs between countries. Australia has a testosterone cream for women; in the United States, at the time this article was written, there was no FDA-approved female-specific testosterone formulation. Approval in another country does not directly translate into authorization in China, still less replace an individual clinical assessment.

The central question at this FDA workshop was how future applicants developing female-specific products should define the target population, demonstrate efficacy, control dosing, and accumulate safety evidence. The workshop itself does not change existing drug approval status.[4]

36 trials

Randomized trials included in the 2019 systematic review [2]

8,480 participants

Total sample size across those trials [2]

0.85 events/month

Mean difference in satisfying sexual events, 95% CI 0.52–1.18 [2]

Original article illustration

Sumatra and surrounding straits · NASA space photography (s43-151-238)

4. Risks and benefits: making the accounting transparent

The same evidence cannot substitute for both efficacy and risk assessment. Short-term randomized trials can estimate average symptom changes; less common adverse events with longer latency require longer follow-up and larger samples.

Known benefits

In postmenopausal women who have undergone complete assessment and have HSDD, randomized trials find average improvements in satisfying sexual events, desire, and associated distress.[1,2] This cannot be extended into a promise to treat fatigue or depression, or to improve overall quality of life.

Known dose-related effects

Androgen-related adverse effects reported in randomized trials and guidelines include acne and increased body hair. Voice changes and clitoral enlargement require particular vigilance, especially by avoiding exposure beyond the physiological range. Incidence varies with formulation, dose, and observation period; a universal “5%–10%” cannot replace individual risk assessment. Adverse effects should prompt a timely follow-up visit, rather than self-adjustment of the dose.[1–3]

Cardiovascular and breast outcomes: long-term safety still needs assessment

Cardiovascular and breast safety cannot be skipped when discussing long-term treatment. Most existing trials have short observation periods, generally insufficient to determine risks of rare events over the long term. The 2019 global consensus explicitly notes insufficient safety data beyond 24 months.[1] Two papers that are easily conflated deserve separate consideration:

  • 2024 insurance-claims database study [5]: In the overall adult female sample, use was associated with fewer major cardiovascular events (RR 0.64). But in the subgroup aged 56 and older, the RR was 0.84 (95% CI 0.64–1.10). The interval crosses 1, so a clear protective effect cannot be claimed in that age group. Claims data are also affected by prescribing selection, baseline health differences, and residual confounding, and cannot demonstrate that testosterone “protects the heart.”
  • 2012 LibiGel paper [6]: White et al. describe the design and implementation plan of a long-term safety trial in women at high cardiovascular risk. It cannot be cited as a result showing that “the trial established no increase in cardiovascular or breast-cancer risk.”
  • Formulations cannot be treated interchangeably: Oral testosterone affects lipids differently from transdermal treatment. The global consensus does not recommend oral formulations, nor does it support using observational findings about a particular implant to promote “breast-cancer prevention.”[1]

Keep the language measured:

Short-term randomized trials help identify common adverse effects, but cannot rule out rare events after years of use. It is currently inappropriate to claim that testosterone “protects the heart” or “prevents cancer,” or to conclude from absent long-term evidence that it is necessarily harmful. Clinical decisions should strictly limit indications and disclose unknown risks honestly.[1,3]

Original article illustration

Sulawesi Island · NASA/JPL space imagery (PIA26007)

Route matters more than a simple “use it or not”

The ISSWSH guideline discusses transdermal administration with controllable dosing and recommends maintaining total testosterone in the female physiological range. It does not recommend implants or intramuscular injections that can cause excessive exposure, or compounded preparations whose quality is difficult to standardize.[3] In places without an approved female-specific formulation, prescribing and monitoring become more complicated. That does not justify splitting up male formulations yourself or buying them online.

5. Clinical suggestions: for whom, how, and when to stop

Translated into everyday decisions, the evidence yields several practical principles, addressed both to women considering treatment and to clinicians responsible for assessment.

  • First ask “is this HSDD?” rather than “is testosterone low?” Low desire has many causes: depression, certain medications, thyroid dysfunction, relationships and stress, uncontrolled chronic conditions, and more. Proper practice is to complete a “biopsychosocial” assessment, establish persistent low desire that causes distress, and exclude other reversible causes. Testosterone is not a supplement to be added whenever a test result is low.
  • Do not be led by one blood-test number. Diagnosis requires clinical assessment. Baseline total testosterone and repeat testing during treatment mainly help avoid excessive exposure. The method needs sufficient accuracy at low concentrations, and results must be interpreted against the laboratory reference range.[3]
  • Maintain boundaries for route and dose. Favor transdermal treatment at physiological doses, maintaining concentrations within the physiological range of premenopausal women. Avoid implants, injections, and inconsistently prepared compounded formulations wherever possible; use under special circumstances requires close monitoring.
  • Set a reassessment time. ISSWSH recommends regular review of symptom improvement and adverse effects. If a properly conducted trial of about six months produces no clinical benefit, stopping should be considered. Long-term continuation needs repeated assessment.[3]
  • Address other identified problems first. Hot flashes, vaginal dryness, and pain require assessment for their respective treatments. Testosterone does not replace menopausal hormone therapy (MHT) or local treatment, and not everyone using MHT needs added testosterone.[1,3]
  • Use shared decision-making and make the accounting clear. This includes off-label use, limited long-term data, possible out-of-pocket costs (insurance often does not cover it), reversible and irreversible adverse effects, and follow-up frequency. Being informed is a prerequisite for this treatment.

The most practical first action is to “bring records to the consultation.” Before considering testosterone, spend two to four weeks keeping a brief symptom diary: how long low desire has persisted, whether it accompanies low mood or reduced energy, the extent of distress related to sex, whether estrogen is already being used appropriately, and what other medications are taken. Bringing that record helps a clinician judge the situation more than simply saying “I seem to be missing something.” Remember, a responsible consultation should be able to conclude “not suitable at present.” If a provider describes testosterone as “something everyone should supplement, with no threshold,” that itself is a warning sign.

Original article illustration

Jakarta and the Java Sea at night · NASA International Space Station photography (iss073e0222649)

What to watch for after this public workshop

The FDA docket for public comments was FDA-2026-N-5479, with an October 19, 2026 deadline. Whether a drug application will be submitted, receive approval, what its label will say, and whether insurance will cover it are all unresolved. Reproducible doses, appropriate efficacy endpoints, and studies sufficient to assess safety are needed—not an inference from one workshop that regulators have already given clearance.[4]

6. Literature at a glance for clinician readers

The original sources below are organized by evidence type. They address different questions and cannot replace one another:

  • [1] Global consensus: Davis SR, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Sex Med. 2019;16:1331–1337. doi:10.1016/j.jsxm.2019.07.012; PMID 31488288. Defines the postmenopausal HSDD indication and the lack of long-term evidence.
  • [2] Review of randomized trials: Islam RM, et al. Lancet Diabetes Endocrinol. 2019;7:754–766. doi:10.1016/S2213-8587(19)30189-5; PMID 31353194. 36 trials, 8,480 participants, mean difference in satisfying sexual events 0.85/month (95% CI 0.52–1.18).
  • [3] Clinical guideline: Parish SJ, et al. J Sex Med. 2021;18:849–867. doi:10.1016/j.jsxm.2020.10.009; PMID 33814355. Recommendations on assessment, transdermal use, monitoring, and stopping.
  • [4] Original regulatory document: FDA. Testosterone Use in Menopausal Women: Public Workshop; Request for Comments. Federal Register, 2026-08-18, document 2026-16829; meeting 2026-09-17; docket FDA-2026-N-5479. Original Federal Register notice.
  • [5] Observational study: Agrawal P, et al. J Sex Med. 2024;21:414–419. doi:10.1093/jsxmed/qdae032; PMID 38459625. Findings differed between adult women overall and the subgroup aged ≥56, and do not establish causation.
  • [6] Study protocol, not results: White WB, et al. Am Heart J. 2012;163:27–32. doi:10.1016/j.ahj.2011.09.021; PMID 22172433. Describes the LibiGel long-term safety trial design.

7. Clinical questions still need clinical evidence

The September 17 FDA workshop did not deliver an “approval” or “prohibition.” It brought an existing clinical question into public discussion: for some postmenopausal women with HSDD, short-term efficacy evidence exists; for long-term cardiovascular and breast safety, sufficiently certain answers are still lacking.[1–4]

A public workshop also cannot replace the review process required for marketing authorization.[4]

If persistent low desire is causing distress, take symptom records to a consultation and discuss pain, mood, relationships, medication, and other reversible factors. Only after a complete assessment can clinician and patient discuss testosterone’s potential benefits, short-term adverse effects, and long-term unknown risks. Self-use for “fatigue” or “antiaging” falls outside the support of this evidence.[1,3]

For decisions now, the most useful distinction remains between “what symptoms do I have?” and “what has this treatment been shown to improve?” An overlap between those two is what makes a further discussion of dose and monitoring worthwhile.

Original article illustration

Sumatra Island · NASA/JPL space imagery (PIA00955)

Disclaimer:

This educational article is based on publicly available literature and regulatory information through October 2026, and is not individualized medical advice. Whether to use testosterone, by which route, and at what dose must be jointly decided with a qualified clinician considering personal history, contraindications, and monitoring results, in accordance with the guidelines of the country concerned. Historical formulations are mentioned only to explain regulatory developments, not as recommendations.

References: [1] Davis et al., 2019, PMID 31488288; [2] Islam et al., 2019, PMID 31353194; [3] Parish et al., 2021, PMID 33814355; [4] FDA, Federal Register document 2026-16829; [5] Agrawal et al., 2024, PMID 38459625; [6] White et al., 2012, PMID 22172433. All Indonesian imagery comes from NASA Images. These are space photographs/remote-sensing images, not ground-level travel photographs, and are unrelated to the medical evidence.

SOURCE NOTES

Read the source material

The original archive manuscript is restored above. These additional references offer context; their inclusion does not constitute medical validation of every original claim. Clinical and regional terminology review are pending.

GINGERA / COMMUNITY

A good question starts a conversation.

Explore a related editorial discussion. Reading is open to everyone; posting and replying require a free reader account.

Create a free accountDiscuss living well